Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0000950170-24-010477 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-02-02 | 2024-01-31 | BEAM | Evans John M. | CEO, Dir | S - Sale | $25.33 | -60.0K | 1.06M | -5% | -$1.52M |
| DT | 2024-02-02 | 2024-01-31 | BEAM | Evans John M. | CEO, Dir | A - Grant | $24.40 | +155.0K | 155.0K | New | +$3.78M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-31 | S | D | 60,000 | $25.33 | 1,058,262 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $24.93 to $25.92 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-31 | A | A | 155,000 | $24.40 | 155,000 | D | $24.40 · — to 2034-01-31 | 155,000 Common Stock | (F4) This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. |